https://pubmed.ncbi.nlm.nih.gov/38603953/
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An...
Pembrolizumab and epacadostat demonstrated an ORR of 21% in this small cohort of recurrent OCCC. The rapid rate of accrual highlights the enthusiasm and need...